Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease

Background Elevated plasma (Lp(a)) levels may represent an independent risk factor for atherothrombotic complications but the relation between Lp(a) levels and the extent of coronary artery disease (CHD) has been discussed controversially. Little is known about potential atherothrombogenic mechanisms of Lp(a). Design Case—control study. Methods We assessed the relationship between plasma Lp(a) and angiographically defined CHD, evaluating the severity of coronary atherosclerosis by three different scores. A total of 312 patients with stable angina aged 40-68 years with at least one coronary stenosis > 50% were studied. A group of 479 voluntary blood donors matched for age and sex served as controls. A complete lipid profile and a large number of markers of coagulation, fibrinolysis and inflammation were measured. Results Plasma levels of Lp(a) were significantly higher in patients (14.8 mg/dl; 5.4-47.1 mg/dl; median/interquartile range) than in controls (9.7 mg/dl; 3.5-25.3) (P>0.0001). In a logistic regression model, the fully adjusted Odds Ratio for CHD was 3.3 (95% confidence interval (CI) 1.8-5.6, P >0.0001) for patients in the upper quartile of the Lp(a) distribution compared to the bottom quartile. There was no appreciable association between Lp(a) and apolipoproteins, markers of haemostasis, fibrinolysis and inflammation and the severity of CHD. Conclusions These results indicate that elevated plasma Lp(a) levels may be an independent risk factor for CHD but unrelated to the severity and extension of CHD. Furthermore, there is no good evidence that the presumed link between Lp(a) and CHD is mediated by increased levels of markers of inflammation, or interference with markers of fibrinolysis or coagulation.

[1]  A. von Eckardstein,et al.  Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. , 2001, Journal of the American College of Cardiology.

[2]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[3]  G. Lowe,et al.  Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. , 2000, Clinical chemistry.

[4]  D. Wilcken,et al.  Lp(a) and conventional risk profiles predict the severity of coronary stenosis in high-risk hospital-based patients. , 2000, Australian and New Zealand journal of medicine.

[5]  N. Yoshida,et al.  Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm. , 2000, Journal of the American College of Cardiology.

[6]  E. Angles-cano,et al.  Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[7]  G. Dangas,et al.  Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. , 1998, Journal of the American College of Cardiology.

[8]  D. Lane,et al.  Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. , 1998, European heart journal.

[9]  P. Ridker,et al.  Lipoprotein (a), Lipids, Aspirin, and Risk of Myocardial Infarction in the Physician's Health Study , 1998, Journal of cardiovascular risk.

[10]  J. Kaski,et al.  Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris. , 1998, Journal of the American College of Cardiology.

[11]  G. Dagenais,et al.  Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. , 1998, Journal of the American College of Cardiology.

[12]  P. Harpel,et al.  Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. , 1997, Circulation.

[13]  K. Bailey,et al.  Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. , 1997, Circulation.

[14]  R. Rosenson,et al.  Lipoprotein Lp(a) excess and coronary heart disease. , 1997, Archives of internal medicine.

[15]  D. Nagel,et al.  Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. , 1997, Atherosclerosis.

[16]  S. Fortmann,et al.  A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[17]  M. Ikäheimo,et al.  Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. , 1996, Atherosclerosis.

[18]  A. Dobson,et al.  Risk of primary and recurrent acute myocardial infarction from lipoprotein(a) in men and women. , 1996, Journal of the American College of Cardiology.

[19]  P. Wilson,et al.  Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.

[20]  D. Sgoutas,et al.  Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells. , 1996, Atherosclerosis.

[21]  C. Nienaber,et al.  Differences in lipoprotein (a) and apolipoprotein (a) levels in men and women with advanced coronary atherosclerosis , 1995, Coronary artery disease.

[22]  G. Breithardt,et al.  Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[23]  P. Wilson,et al.  A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. , 1994, Circulation.

[24]  R. Muche,et al.  Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS) , 1994, European journal of clinical investigation.

[25]  D. Wilcken,et al.  Determinants of severity of coronary artery disease in Australian men and women. , 1994, Circulation.

[26]  J. Ordovás,et al.  Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. , 1994, JAMA.

[27]  J. Salonen,et al.  Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. , 1994, Atherosclerosis.

[28]  N. Wald,et al.  Apolipoproteins and ischaemic heart disease: implications for screening , 1994, The Lancet.

[29]  R. Lawn,et al.  The relationship of lipoprotein (a) to hemostasis , 1993 .

[30]  P. Ridker,et al.  A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.

[31]  G. De Backer,et al.  Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. , 1992, Clinical chemistry.

[32]  G. Thorgeirsson,et al.  Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. , 1992, The American journal of cardiology.

[33]  M. Pike,et al.  A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. , 1992, Atherosclerosis.

[34]  U. Beisiegel.  Lipoprotein (a) in the arterial wall , 1991, European heart journal.

[35]  J. Huttunen,et al.  Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. , 1991, Atherosclerosis.

[36]  K. Hajjar,et al.  Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. , 1991, The Journal of biological chemistry.

[37]  L. Wilhelmsen,et al.  Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. , 1990, BMJ.

[38]  G. Roubin,et al.  Predictive value of lipoprotein (a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. , 1990, The American journal of cardiology.

[39]  E. Plow,et al.  Lp(a): An Interloper into the Fibrinolytic System? , 1990, Thrombosis and Haemostasis.

[40]  J. Loscalzo,et al.  Lipoprotein(a), fibrin binding, and plasminogen activation. , 1990, Arteriosclerosis.

[41]  W. Parmley.  Prevalence and Clinical Significance of Silent Myocardial Ischemia , 1989, Circulation.

[42]  M. Seishima,et al.  Transient changes of serum lipoprotein(a) as an acute phase protein. , 1989, Atherosclerosis.

[43]  J. Breslow,et al.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis , 1989, Nature.

[44]  A. Scanu,et al.  A potential basis for the thrombotic risks associated with lipoprotein(a) , 1989, Nature.

[45]  N. Morton,et al.  Lp(a) lipoprotein as a risk factor for myocardial infarction. , 1986, JAMA.

[46]  S. Humphries,et al.  Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. , 2001, The American journal of medicine.

[47]  K. Hajjar,et al.  The role of lipoprotein(a) in atherogenesis and thrombosis. , 1996, Annual review of medicine.

[48]  A. Gotto,et al.  CORONARY ARTERY DISEASE Association of levels of lipoprotein Lp ( a ) , plasma lipids , and other lipoproteins with coronary artery disease documented by angiography , 2022 .